• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by TELA Bio Inc.

    3/21/25 4:35:43 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care
    Get the next $TELA alert in real time by email
    S-8 1 tm259851d1_s8.htm FORM S-8

     

    As filed with the United States Securities and Exchange Commission on March 21, 2025 

    Registration No. 333-

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    FORM S-8 

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    TELA BIO, INC. 

    (Exact name of registrant as specified in its charter)

     

    Delaware    45-5320061
    (State or other jurisdiction of incorporation or
    organization)
      (I.R.S. Employer Identification No.)

     

    1 Great Valley Parkway, Suite 24
    Malvern, Pennsylvania
      19355
    (Address of Principal Executive Offices)   (Zip Code)

     

    RESTRICTED STOCK UNIT INDUCEMENT AWARDS 

    (Full title of the plan)

     

    Antony Koblish
    President and Chief Executive Officer
    TELA Bio, Inc.
    1 Great Valley Parkway, Suite 24
     

    Malvern, Pennsylvania 19355 

    (Name and address of agent for service)

     

    (484) 320-2930
    (Telephone number, including area code, of agent for service)

     

    Copies to: 

    Rachael M. Bushey, Esq.
    Justin S. Platt, Esq.
    Goodwin Procter LLP

    3025 John F Kennedy Blvd
    Philadelphia, PA 19104
    (445) 207-7805

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 registers shares of common stock, $0.001 par value per share (the “Common Stock”), of TELA Bio, Inc. (the “Registrant”) issuable pursuant to the inducement awards, as described below. As a material inducement to the individuals listed below to accept employment with the Registrant, the Registrant granted the following equity awards to such individuals (the “Inducement Awards”) on the dates detailed below:

     

    ·Restricted stock unit awards (“RSU Awards”) with respect to an aggregate of 20,250 shares of Common Stock granted to 11 newly-hired employees on May 6, 2024;
    ·RSU Awards with respect to an aggregate of 16,000 shares of Common Stock granted to 9 newly-hired employees on August 6, 2024;
    ·RSU Awards with respect to an aggregate of 5,400 shares of Common Stock granted to 6 newly-hired employees on November 1, 2024;
    ·RSU Awards with respect to an aggregate of 1,700 shares of Common Stock granted to 3 newly-hired employees on December 11, 2024;
    ·RSU Awards with respect to an aggregate of 4,000 shares of Common Stock granted to 7 newly-hired employees on January 24, 2025; and
    ·RSU Awards with respect to an aggregate of 7,200 shares of Common Stock granted to 13 newly-hired employees on February 21, 2025.

     

    Each Inducement Award was approved by the Registrant’s Compensation Committee of the Board of Directors in compliance with and in reliance on Nasdaq Listing Rule 5635(c)(4). The Inducement Awards were granted outside of the Registrant’s Amended and Restated 2019 Equity Incentive Plan and its predecessor plans.

     

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Part I of Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of the Form S-8 instructions. The documents containing the information specified in Part I will be delivered to persons to whom the Inducement Awards have been granted as required by Rule 428(b)(1) under the Securities Act.

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have been filed by the Registrant with the Securities and Exchange Commission (the “Commission”) are incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

     

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 21, 2025;

     

    (b) The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on November 7, 2019 (File No. 001-39130), together with any amendment thereto filed with the Commission for the purpose of updating such description; and

     

    (c) All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment to this Registration Statement, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement; provided, however, that documents, reports and definitive proxy or information statements, or portions thereof, which are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement.

     

     

     

     

    Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    The following summary is qualified in its entirety by reference to the complete Delaware General Corporation Law (“DGCL”) and the Registrant’s Third Amended and Restated Bylaws.

     

    The Registrant is governed by the DGCL. Section 145 of the DGCL provides that a corporation may indemnify any person, including an officer or director, who was or is, or is threatened to be made, a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person was or is an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such officer, director, employee or agent acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the corporation’s best interest and, for criminal actions or proceedings, had no reasonable cause to believe that such person’s conduct was unlawful. A Delaware corporation may indemnify any person, including an officer or director, who was or is, or is threatened to be made, a party to any threatened, pending or completed action or suit by or in the right of such corporation, under the same conditions, except that such indemnification is limited to expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and except that no indemnification is permitted without judicial approval if such person is adjudged to be liable to such corporation. Where an officer or director of a corporation is successful, on the merits or otherwise, in the defense of any action, suit or proceeding referred to above, or any claim, issue or matter therein, the corporation must indemnify that person against the expenses (including attorneys’ fees) which such officer or director actually and reasonably incurred in connection therewith.

     

    The Registrant’s Third Amended and Restated Bylaws provide that:

     

    · The Registrant will indemnify its directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and

     

    · The Registrant will advance reasonable expenses incurred by or on behalf of its directors and, at the discretion of the Registrant’s Board of Directors, any officer or non-officer employee in connection with legal proceedings relating to their service for or on behalf of the Registrant.

     

     

     

     

    The Registrant has entered into indemnification agreements with each of its directors and certain of its officers. These agreements provide that the Registrant will indemnify each of its directors and certain of its officers to the fullest extent permitted by Delaware law.

     

    The Registrant will advance expenses, including attorneys’ fees (but excluding judgments, fines and settlement amounts), to each indemnified director or executive officer in connection with any proceeding in which indemnification is available and the Registrant will indemnify our directors and officers for any action or proceeding arising out of that person’s services as a director or officer brought on behalf of the Registrant or in furtherance of the Registrant’s rights.

     

    The Registrant also maintains general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers and the Registrant intends to maintain such coverage.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    The following documents are filed as exhibits to this Registration Statement:

     

    Exhibit
    Number
      Description of Exhibit
    3.1   Fourth Amended and Restated Certificate of Incorporation of TELA Bio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-39130) filed on November 19, 2019).
    3.2   Third Amended and Restated Bylaws of TELA Bio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-39130) filed on November 13, 2023).
    4.1   Form of Certificate of Common Stock (incorporated herein by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1 (File No. 333-234217) filed on October 29, 2019).
    5.1*   Opinion of Goodwin Procter LLP as to the legality of the securities being registered.
    23.1*   Consent of KPMG LLP, independent registered public accounting firm for TELA Bio, Inc.
    23.2*   Consent of Goodwin Procter LLP (contained in Exhibit 5.1).
    24.1*   Power of Attorney (included on the signature page of the Registration Statement).
    99.1#   Form of TELA Bio, Inc. Inducement Award Agreement for Restricted Stock Unit (incorporated herein by reference to Exhibit 10.17 of the Company’s Annual Report on Form 10-K (File No. 001-39130) filed on March 23, 2023).
    107*   Filing Fee Table.

     

    * Filed herewith
    # Denotes management contract or compensatory plan or arrangement.

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

     

     

     

    (ii) to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

     

    (iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Borough of Malvern, Commonwealth of Pennsylvania, on March 21, 2025.

     

    TELA BIO, INC.  
         
    By: /s/ Antony Koblish  
      Antony Koblish  
      President, Chief Executive Officer and Director  

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of Antony Koblish and Roberto Cuca as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature    Title    Date 
             
    /s/ Antony Koblish   President, Chief Executive Officer and Director   March 21, 2025
    Antony Koblish   (Principal Executive Officer)    
             
    /s/ Roberto Cuca   Chief Operating Officer and Chief Financial Officer   March 21, 2025
    Roberto Cuca   (Principal Financial Officer)    
             
    /s/ Megan Smeykal   Chief Accounting Officer and Controller   March 21, 2025
    Megan Smeykal   (Principal Accounting Officer)    
             
    /s/ Doug Evans   Chairman, Board of Directors   March 21, 2025
    Doug Evans        
             
    /s/ Kurt Azarbazin   Director   March 21, 2025
    Kurt Azarbazin        
             
    /s/ Vince Burgess   Director   March 21, 2025
    Vince Burgess        
             
    /s/ Lisa Colleran   Director   March 21, 2025
    Lisa Colleran        
             
    /s/ Federica O’Brien   Director   March 21, 2025
    Federica O’Brien        
             
    /s/ Jeffrey Blizard   Director   March 21, 2025
    Jeffrey Blizard        

     

     

     

    Get the next $TELA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TELA

    DatePrice TargetRatingAnalyst
    3/21/2025$5.00 → $2.00Overweight → Neutral
    Piper Sandler
    5/31/2022$17.00Buy
    Lake Street
    More analyst ratings

    $TELA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ew Healthcare Partners Fund 2, L.P. bought $4,000,440 worth of shares (3,604,000 units at $1.11), increasing direct ownership by 88% to 7,714,709 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    11/17/25 4:26:15 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Director Plovanic William J. was granted 11,925 shares (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    11/3/25 4:22:34 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Plovanic William J.

    3 - TELA Bio, Inc. (0001561921) (Issuer)

    11/3/25 4:19:21 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 3,600 shares of its common stock to three newly-hired employees, with a grant date of December 9, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or h

    12/12/25 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

    MALVERN, Pa., Nov. 19, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 37th Annual Healthcare Conference. TELA's management is scheduled to present at Piper Sandler's 37th Annual Healthcare Conference at 2:30 pm ET on December 3rd, 2025. Interested parties can access the live and archived webcast at ir.telabio.com. About TELA Bio, Inc.TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritiz

    11/19/25 8:30:00 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of (i) restricted stock units covering 30,200 shares of its common stock to seventeen newly-hired employees and (ii) an option to purchase 25,000 shares of its common stock to one employee, with a grant date of November 10, 2025 (the "Grant Date"). The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individua

    11/17/25 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    SEC Filings

    View All

    SEC Form S-3 filed by TELA Bio Inc.

    S-3 - TELA Bio, Inc. (0001561921) (Filer)

    12/12/25 7:11:07 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - TELA Bio, Inc. (0001561921) (Filer)

    11/14/25 4:38:45 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by TELA Bio Inc.

    424B5 - TELA Bio, Inc. (0001561921) (Filer)

    11/14/25 4:20:56 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $TELA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Large owner Ew Healthcare Partners Fund 2, L.P. bought $4,000,440 worth of shares (3,604,000 units at $1.11), increasing direct ownership by 88% to 7,714,709 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    11/17/25 4:26:15 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    COO and CFO Cuca Roberto bought $144,999 worth of shares (64,444 units at $2.25), increasing direct ownership by 71% to 155,388 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    10/24/24 4:26:40 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Chief Technology Officer Talmo Paul bought $50,000 worth of shares (22,222 units at $2.25), increasing direct ownership by 32% to 91,082 units (SEC Form 4)

    4 - TELA Bio, Inc. (0001561921) (Issuer)

    10/24/24 4:25:59 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded TELA Bio from Overweight to Neutral and set a new price target of $2.00 from $5.00 previously

    3/21/25 8:05:03 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Lake Street initiated coverage on TELA Bio with a new price target

    Lake Street initiated coverage of TELA Bio with a rating of Buy and set a new price target of $17.00

    5/31/22 9:13:36 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Leadership Updates

    Live Leadership Updates

    View All

    TELA Bio Appoints William Plovanic to Board of Directors

    MALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of William ("Bill") Plovanic, CFA, to its Board of Directors. Mr. Plovanic brings a distinctive combination of capital markets expertise and operational leadership in medical technology. He currently serves as Managing Director, Healthcare Equity Research at Canaccord Genuity. From 2016 to 2021, he held C-level operating and board roles at Obalon Therapeutics, a formerly publicly traded medical device com

    11/3/25 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran

    MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors, and the departure of Lisa Colleran, who has stepped down following five years of service on the Board. Dr. Rocchio is a nationally recognized healthcare leader and one of Modern Healthcare's 50 Most Influential Clinical Executives. She brings decades of experience in advancing clinical excellence, workforce innovation, and supply-chain transformation across some of the nation's l

    10/9/25 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Appoints Jeffrey Blizard as President

    MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President of TELA Bio, effective immediately. Mr. Blizard, who has served on TELA Bio's Board of Directors for the past year, brings deep industry experience and proven leadership to this expanded role. "This is an important inflection point for TELA Bio," said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. "As we move into the next phase of our growth trajectory, we believe the addition of Jeff—a highly respected l

    6/2/25 8:30:00 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    $TELA
    Financials

    Live finance-specific insights

    View All

    $TELA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility

    MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $20.7 million, a 9% increase from the third quarter of 2024Revised full year 2025 revenue guidance of at least 16% growth over full year 2024 Recent Strategic Highlights Strengthened capital position with a credit facility up to $70.0 million debt with Perceptive AdvisorsExpanded Board capabilities with appointments of Betty Jo Rocchio and Bill PlovanicAccelerated hi

    11/13/25 4:01:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio to Announce Third Quarter 2025 Financial Results

    MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes befor

    11/4/25 8:30:00 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio Reports Second Quarter 2025 Financial Results

    MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights Delivered revenue of $20.2 million in the second quarter 2025, representing growth of 26% over the prior year period and sequential growth of 9% over the first quarter of 2025;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the second quarter, resulting in year-over-year revenue increase for each product of approximately 12% and 53%, respectively;Appointed Jeffrey Bliz

    8/11/25 4:03:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

    SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

    11/14/24 1:06:57 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by TELA Bio Inc.

    SC 13G - TELA Bio, Inc. (0001561921) (Subject)

    10/29/24 5:12:40 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

    SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

    10/28/24 4:06:51 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care